They Just Don't Get...
Health Care: Drugs
AspenBio Pharma Inc. (APPY: NASDAQ)
$0.49 0.01 | 2.51%
06/04/12 - 10:18 AM ET
Ratio Comparisons
| Company | Industry | S&P 500 | |
| Valuation Ratios | |||
|---|---|---|---|
| P/E Ratio (TTM) | n.a. | 173.50 | 17.70 |
| P/E High - Last 5 Yrs | n.a. | n.a. | 67.70 |
| P/E Low - Last 5 Yrs | n.a. | n.a. | 12.50 |
| Beta | 1.01 | 0.96 | 0.98 |
| Price to Sales (TTM) | 26.56 | 4.16 | 1.42 |
| Price to Book (MRQ) | 2.19 | 3.92 | 2.41 |
| Price to Tangible Book (MRQ) | 8.49 | 5.44 | 5.08 |
| Price to Cash Flow (TTM) | -0.50 | 46.50 | 9.80 |
| Price to Free Cash Flow (TTM) | -0.60 | -315.20 | 17.40 |
| Dividends | |||
| Dividend Yield (%) | 0.00 | 0.30 | 2.10 |
| Dividend Yield - 5 Yr Avg (%) | n.a. | 0.30 | 2.20 |
| Dividend 5 Yr Growth Rate (%) | n.a. | 35.82 | -0.76 |
| Payout Ratio (TTM) | 0.00 | 63.00 | 30.00 |
| Sales (MRQ) vs Qtr 1 Yr Ago (%) | -93.70 | 6.80 | 11.80 |
| Sales (TTM) vs TTM 1 Yr Ago (%) | -23.90 | -3.40 | 9.20 |
| Growth Rates (%) | |||
| Sales - 5 Yr Growth Rate (%) | -26.35 | 0.00 | 1.79 |
| EPS (MRQ) vs Qtr 1 Yr Ago (%) | n.a. | -93.00 | 17.50 |
| EPS (TTM) vs TTM 1 Yr Ago (%) | n.a. | -93.00 | 17.50 |
| EPS - 5 Yr Growth Rate (%) | n.a. | n.a. | -1.66 |
| Capital Spending - 5 Yr Growth Rate (%) | -16.83 | -9.04 | -1.17 |
| Financial Strength | |||
| Quick Ratio (MRQ) | 1.10 | 2.90 | 1.10 |
| Current Ratio (MRQ) | 1.30 | 3.60 | 1.60 |
| LT Debt to Equity (MRQ) | 1.23 | 0.04 | 0.82 |
| Total Debt to Equity (MRQ) | 1.69 | 0.09 | 0.96 |
| Interest Coverage (TTM) | n.a. | 22.20 | 5.50 |
| Profitability Ratios (%) | |||
| Gross Margin (TTM) | n.a. | 62.80 | 46.90 |
| Gross Margin - 5 Yr Avg | 95.30 | 63.90 | 47.70 |
| EBITD Margin (TTM) | n.a. | 15.20 | 18.90 |
| EBITD - 5 Yr Avg | -754.76 | 0.00 | 0.00 |
| Pre-Tax Margin (TTM) | n.a. | 8.80 | 12.10 |
| Pre-Tax Margin - 5 Yr Avg | n.a. | -0.50 | 10.30 |
| Management Effectiveness (%) | |||
| Net Profit Margin (TTM) | -53.78 | 0.03 | 0.09 |
| Net Profit Margin - 5 Yr Avg | n.a. | -6.20 | 7.00 |
| Return on Assets (TTM) | -146.80 | 1.90 | 3.10 |
| Return on Assets - 5 Yr Avg | -54.20 | -4.20 | 2.50 |
| Return on Investment (TTM) | -198.00 | 2.40 | 7.90 |
| Return on Investment - 5 Yr Avg | -63.80 | -5.80 | 6.50 |
| Efficiency | |||
| Revenue/Employee (TTM) | 7,556.00 | 229,628.00 | 449,376.00 |
| Net Income/Employee (TTM) | -406,358.00 | 6,227.00 | 39,003.00 |
| Receivable Turnover (TTM) | 4.60 | 7.10 | 7.60 |
| Inventory Turnover (TTM) | -189.40 | 3.00 | 8.30 |
| Asset Turnover (TTM) | 0.00 | 0.70 | 0.40 |
Portfolios with APPY
- Portfolio NameUser Type
- UserSUPRATRADE-2709091838
- UserBrahmsian's Debt/Equity Por...
- UserBrahmsian's Financially Sou...
- Userdan vosika Portfolio 1
- Usergame on
- Userdreamerl3oi Portfolio 1
- Useremannn Portfolio 1
- UserKBEE Portfolio 1
- UserMoney and Suits Portfolio 1
- UserFly Me To The Moon Monster ...
Latest APPY Headlines from TheStreet
- Biotech Sector Weekly Rewind 11.13.10 | 07:11 am
- Vantage Drilling, First M&F: Volume Movers 07.20.10 | 07:07 am
- AspenBio Finds Fault Afar for Failure 07.20.10 | 06:07 am
- Biotech Stock Mailbag: Spectrum Pharma 06.18.10 | 07:06 am
- Hellenic Telecom, AspenBio Pharma: Midday Volume Plays 06.07.10 | 12:06 pm
- Stock Offerings: Navios Maritime 04.30.10 | 11:04 am
- Biotech Stock Mailbag: AspenBio 04.30.10 | 06:04 am
- ClickSoftware, AspenBio: Early Volume Plays 12.29.09 | 07:12 am
- AspenBio Pharma Prices Public Offering 10.07.09 | 08:10 am
- Biotech News Roundup: Aspen, AMAG, Vertex 08.17.09 | 12:08 pm
Press Releases for APPY
- AspenBio Appoints Diagnostics Industry Veteran Don Hurd As Senior Vice President And Chief Commercial Officer - Business Wire 05.24.12 | 09:05 am
- AspenBio Pharma’s Clinical Study Suggests One-Third Of CT Scans Used To Assess Pediatric And Adolescent Patients At Low Risk For Acute Appendicitis Could Potentially Be Avoided - Business Wire 04.18.12 | 09:04 am
- Results Of 503-Patient Clinical Study Of AspenBio Pharma’s AppyScore™ Blood Test Show 97% Negative Predictive Value For Absence Of Acute Appendicitis In Children And Adolescents Presenting With Abdominal Pain - Business Wire 03.16.12 | 02:03 pm
- Study Demonstrates AspenBio Pharma’s AppyScore Multi-Marker Blood Test Highly Predictive For Absence Of Acute Appendicitis In Children With Abdominal Pain - Business Wire 02.28.12 | 09:02 am
- Rigrodsky & Long, P.A. Announces Class Action Lawsuit Against AspenBio Pharma, Inc. - Business Wire 10.07.10 | 04:10 pm
- The Law Office Of Robbins Umeda LLP Announces The Filing Of A Class Action Suit Against AspenBio Pharma, Inc. - Business Wire 10.07.10 | 04:10 pm
- Investor Notice: The Rosen Law Firm Announces Investigation Of Shareholder Securities Claims Against AspenBio Pharma, Inc. --- APPY - Business Wire 09.03.10 | 08:09 pm
Partner Headlines for APPY
- Morning Market Losers - Benzinga 12.19.11 | 09:12 am
- AspenBio Pharma Reports AppyScore(TM) ELISA-Based Pivotal Trial Results and Outlines Plans for AppyScore Cassette-Based Test - Benzinga 07.19.10 | 04:07 pm
- AspenBio Pharma Shares Plummet on Drug Application Delay - Fox Business 06.07.10 | 04:06 pm
- 4 Small Cap Biotechs To Keep an Eye On - Seeking Alpha 05.26.10 | 04:05 pm
- Thursday Outlook: What, Me Worry? - Seeking Alpha 05.13.10 | 10:05 am
- Biotech CROs Take Center Stage in Recent Deals - Seeking Alpha 05.02.10 | 05:05 am
- Takeover Speculation Swarms at AspenBio Pharma - SeekingAlpha.com 04.26.10 | 03:04 am
- Preview of AspenBio's Potentially Blockbuster Clinical Trials - SeekingAlpha.com 04.25.10 | 08:04 am
- Friday Options Recap - SeekingAlpha.com 04.23.10 | 03:04 pm
- Will AspenBio Pharma Follow in Dendreon and Human Genome Sciences' Footsteps? - SeekingAlpha.com 04.22.10 | 04:04 am
